Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic profile based on the relevant PK modeling data
Additional.
Nearly 98% of patients experience quality of life impact as a result of tardive dyskinesia including social, psychological, physical and recreational aspects of daily living
Data highlight for.
U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets
AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular monoamine transporter 2 inhibitor for effective.
Neurocrine Biosciences Announces CEO Succession Plan marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders,